Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development

Cancer Research

Volumn 66, Issue 4, 2006, Pages 2059-2066

  Koller, Erich ^a   Propp, Stephanie ^a   Zhang, Hong ^a   Zhao, Chenguang ^a   Xiao, Xiaokun ^a   Chang, MingYi ^a   Hirsch, Scott A ^a   Shepard, Peter J ^a   Koo, Seongjoon ^a   Murphy, Cain ^a   Glazer, Robert I ^b   Dean, Nicholas M ^a  

^a ISIS PHARMACEUTICALS   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; CELL DNA; EG5 ANTISENSE OLIGONUCLEOTIDE; ISIS 183881; ISIS 183891; ISIS 339395; KINESIN LIKE 1 PROTEIN; PROTEIN EG5; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG SCREENING; GENE EXPRESSION; GENE IDENTIFICATION; GENE TARGETING; GROWTH INHIBITION; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN PHOSPHORYLATION; TUMOR CELL; TUMOR GROWTH; TUMOR XENOGRAFT; VALIDATION PROCESS;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DNA, NEOPLASM; GENE LIBRARY; GLIOMA; HELA CELLS; HUMANS; KINESIN; MICE; MICE, NUDE; OLIGONUCLEOTIDES, ANTISENSE; RNA, MESSENGER; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 33644517511     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-1531     Document Type: Article

References (50)

1. Bhalla KN. Microtubule-targeted anticancer agents and apoptosis. Oncogene 2003;22:9075-86.
2. Nigg EA. Mitotic kinases as regulators of cell division and its checkpoints. Nat Rev Mol Cell Biol 2001;2:21-32.
3. Kawabe T. G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 2004;3:513-9.
4. Harrington EA, Bebbington D, Moore J, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004;10:262-7.
5. Bettencourt-Dias M, Giet R, Sinka R, et al. Genomewide survey of protein kinases required for cell cycle progression. Nature 2004;432:980-7.
6. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nat Cell Biol 2005;7:591-600.
7. Trompouki E, Hatzivassiliou E, Tsichritzis T, et al. CVLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members. Nature 2003;424:793-6.
8. Aza-Blanc P, Cooper CL, Wagner K, et al. Identification of modulators of TRAIL-induced apoptosis via RNAi-based phenotypic screening. Mol Cell 2003;12:627-37.
9. Zheng L, Liu J, Batalov S, et al. An approach to genomewide screens of expressed small interfering RNAs in mammalian cells. Proc Natl Acad Sci U S A 2004;101:135-40.
10. Kittler R, Putz G, Pelletier L, et al. An endoribo-nuclease-prepared siRNA screen in human cells identifies genes essential for cell division. Nature 2004;432:1036-40.
11. McKay RA, Miraglia LJ, Cummins LL, et al. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-α expression. J Biol Chem 1999;274:1715-22.
12. Butler M, McKay RA, Popoff IJ, et al. Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 2002;51:1028-34.
13. Zinker BA, Rondinone CM, Trevillyan JM, et al. PTP1B antisense oligonucleotide lowers PTP1B protein, normalizes blood glucose, and improves insulin sensitivity in diabetic mice. Proc Natl Acad Sci U S A 2002;99:11357-62.
14. Sloop KW, Cao JX, Siesky AM, et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 2004;113:1571-81.
15. Zhang H, Cook J, Nickel J, et al. Reduction of liver Fas expression by an antisense oligonucleotide protects mice from fulminant hepatitis. Nat Biotechnol 2000;18:862-7.
16. Lee Y, Vassilakos A, Feng N, et al. GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. Cancer Res 2003;63:2802-11.
17. Dagenbach EM, Endow SA. A new kinesin tree. J Cell Sci 2004;117:3-7.
18. Cole DG, Saxton WM, Sheehan KB, Scholey JM. A "slow" homotetrameric kinesin-related motor protein purified from Drosophila embryos. J Biol Chem 1994;269:22913-6.
19. Blangy A, Lane HA, d'Herin P, et al. Phosphorylation by p34cdc2 regulates spindle association of human Eg5, a kinesin-related motor essential for bipolar spindle formation in vivo. Cell 1995;83:1159-69.
20. Mayer TU, Kapoor TM, Haggarty SJ, et al. Small molecule inhibitor of mitotic spindle bipolarity identified in a phenotype-based screen. Science 1999;286:971-4.
21. Kapoor TM, Mayer TU, Coughlin ML, Mitchison TJ. Probing spindle assembly mechanisms with monastrol, a small molecule inhibitor of the mitotic kinesin, Eg5. J Cell Biol 2000;150:975-88.
22. Nakazawa J, Yajima J, Usui T, et al. A novel action of terpendole E on the motor activity of mitotic Kinesin Eg5. Chem Biol 2003;10:131-7.
23. DeBonis S, Simorre JP, Crevel I, et al. Interaction of the mitotic inhibitor monastrol with human kinesin Eg5. Biochemistry 2003;42:338-49.
24. Maliga Z, Kapoor TM, Mitchison TJ. Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5. Chem Biol 2002;9:989-96.
25. Ma VY, Bisby MA. Increased activation of nuclear factor κB in rat lumbar dorsal root ganglion neurons following partial sciatic nerve injuries. Brain Res 1998;797:243-54.
26. Marcus AI, Peters U, Thomas SL, et al. Mitotic kinesin inhibitors induce mitotic arrest and cell death in Taxol-resistant and -sensitive cancer cells. J Biol Chem 2005;280:11569-77.
27. Dean NM, McKay R, Condon TP, Bennett CF. Inhibition of protein kinase C-α expression in human A549 cells by antisense oligonucleotides inhibits induction of intercellular adhesion molecule 1 (ICAM-1) mRNA by phorbol esters. J Biol Chem 1994;269:16416-24.
28. Dean NM, Griffey RH. Identification and characterization of second-generation antisense oligonucleotides. Antisense Nucleic Acid Drug Dev 1997;7:229-33.
29. Baker BF, Lot SS, Condon TP, et al. 2′-O-(2-Methoxy)ethyl-modified anti-intercellular adhesion molecule 1 (ICAM-1) oligonucleotides selectively increase the ICAM-1 mRNA level and inhibit formation of the ICAM-1 translation initiation complex in human umbilical vein endothelial cells. J Biol Chem 1997;272:11994-2000.
30. Waring JF, Ciurlionis R, Clampit JE, et al. PTP1B antisense-treated mice show regulation of genes involved in lipogenesis in liver and fat. Mol Cell Endocrinol 2003;203:155-68.
31. Vickers TA, Koo S, Bennett CF, et al. Efficient reduction of target RNAs by small interfering RNA and RNase H-dependent antisense agents. A comparative analysis. J Biol Chem 2003;278:7108-18.
32. Marumoto T, Honda S, Hara T, et al. Aurora-A kinase maintains the fidelity of early and late mitotic events in HeLa cells. J Biol Chem 2003;278:51786-95.
33. Huang JY, Raff JW. The dynamic localisation of the Drosophila APC/C: evidence for the existence of multiple complexes that perform distinct functions and are differentially localised. J Cell Sci 2002;115:2847-56.
34. Topper LM, Campbell MS, Tugendreich S, et al. The dephosphorylated form of the anaphase-promoting complex protein Cdc27/Apc3 concentrates on kinetochores and chromosome arms in mitosis. Cell Cycle 2002;1:282-92.
35. Elez R, Piiper A, Giannini CD, Brendel M, Zeuzem S. Polo-like kinase1, a new target for antisense tumor therapy. Biochem Biophys Res Commun 2000;269:352-6.
36. Norbury C, Nurse P. Animal cell cycles and their control. Annu Rev Biochem 1992;61:441-70.
37. Flanagan WM, Su LL, Wagner RW. Elucidation of gene function using C-5 propyne antisense oligonucleotides. Nat Biotechnol 1996;14:1139-45.
38. Hendzel MJ, Wei Y, Mancini MA, et al. Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation. Chromosoma 1997;106:348-60.
39. Hendzel MJ, Kruhlak MJ, Bazett-Jones DP. Organization of highly acetylated chromatin around sites of heterogeneous nuclear RNA accumulation. Mol Biol Cell 1998;9:2491-507.
40. Hendzel MJ, Nishioka WK, Raymond Y, et al. Chromatin condensation is not associated with apoptosis. J Biol Chem 1998;273:24470-8.
41. Chadee DN, Hendzel MJ, Tylipski CP, et al. Increased Ser-10 phosphorylation of histone H3 in mitogen-stimulated and oncogene-transformed mouse fibroblasts. J Biol Chem 1999;274:24914-20.
42. Castro A, Bernis C, Vigneron S, Labbe JC, Lorca T. The anaphase-promoting complex: a key factor in the regulation of cell cycle. Oncogene 2005;24:314-25.
43. Ma XJ, Salunga R, Tuggle JT, et al. Gene expression profiles of human breast cancer progression. Proc Natl Acad Sci U S A 2003;100:5974-9.
44. Zhu C, Zhao J, Bibikova M, et al. Functional analysis of human microtubule-based motor proteins, the kinesins and dyneins, in mitosis/cytokinesis using RNA interference. Mol Biol Cell 2005;16:3187-99.
45. Sawin KE, Mitchison TJ, Mutations in the kinesin-like protein Eg5 disrupting localization to the mitotic spindle. Proc Natl Acad Sci U S A 1995;92:4289-93.
46. Giet R, Uzbekov R, Cubizolles F, Le Guellec K, Prigent C. The Xenopus laevis aurora-related protein kinase pEg2 associates with and phosphorylates the kinesin-related protein XlEg5. J Biol Chem 1999;274:15005-13.
47. Giet R, Prigent C. The Xenopus laevis aurora/Ip11p-related kinase pEg2 participates in the stability of the bipolar mitotic spindle. Exp Cell Res 2000;258:145-51.
48. Sakowicz R, Finer JT, Beraud C, et al. Antitumor activity of a kinesin inhibitor. Cancer Res 2004;64:3276-80.
49. Gleave M, Miyake H. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer. World J Urol 2005;23:38-46.
50. Dean NM, Bennett CF. Antisense oligonucleotide-based therapeutics for cancer. Oncogene 2003;22:9087-96.